受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 根据东财Choice数据，2025年12月2日，海南海德资本管理股份有限公司（证券代码：000567）融资余 额为1.77亿元，较前一日下降4.53%。值得关注的是，此前公司已因涉嫌信息披露违法违规被监管立 案。 登录新浪财经APP 搜索【信披】查看更多考评等级 投资者维权所需材料 1． 股票交易对账单：需携带身份证至开户的证券公司营业部打印，从首次买入海德股份之日至今的所 有交易记录，并加盖业务印章。尚持有该股票的，对账单应显示剩余股数。 立案基本情况 2025年11月28日，海德股份（维权）发布《关于公司及相关人员收到中国证券监督管理委员会<立案告 知书>的公告》。公告显示，公司及实际控制人王广西于当日收到中国证监会下发的《立案告知书》 （编号：证监立案字0292025006号和0292025007号）。 立案原因：因涉嫌信息披露违法违规，根据《中华人民共和国证券法》《中华人民共和国行政处罚法 ...

Core Viewpoint - Aolian Electronics has been found to have made misleading statements regarding the performance of Xu Mingjun in the perovskite sector, leading to potential legal claims from investors [2][6]. Group 1: Misleading Statements - Aolian Electronics disclosed that Xu Mingjun did not play a leading or key role in 12 related projects, and his involvement was limited to participation rather than significant contributions [3][6]. - The company exaggerated Xu Mingjun's influence and core competencies in the perovskite industry, which misled investors [4][6]. Group 2: Legal Implications - Investors who purchased Aolian Electronics stock between December 12, 2022, and February 21, 2023, and sold or held their shares after February 21, 2023, are eligible to file claims, but the time frame for doing so is limited [5][7]. - The law firm representing investors has successfully secured compensation for some cases and continues to accept claims from affected investors [5][7].

Core Viewpoint - Shanghai Xinyang Semiconductor Materials Co., Ltd. has been found to have engaged in false statements leading to investor claims, with a precedent for winning such claims already established [1][4]. Group 1: Shanghai Xinyang - On September 18, 2024, Shanghai Xinyang announced it received an administrative regulatory measure decision from the Shanghai Securities Regulatory Bureau due to violations [1][4]. - The company failed to recognize the value and fair value changes of a financial derivative product worth 100 million yuan, resulting in an inflated net profit attributable to shareholders by 13.5285 million yuan [1][4]. - The inaccurate information disclosure in the Q1 2024 report violated the regulations of the "Management Measures for Information Disclosure of Listed Companies" [1][4]. Group 2: Investor Claims - Investors who purchased Shanghai Xinyang shares between April 20, 2024, and August 17, 2024, and sold or continued to hold after August 17, 2024, are eligible to initiate claims [2][5]. - The law firm representing investors has also been involved in claims against Weichuang Co., which is currently awaiting further court arrangements [2][5]. Group 3: Weichuang Co. - Weichuang Co. has been found to have multiple violations regarding information disclosure, including failing to disclose changes in actual control and related party transactions [3][6]. - Investors who bought Weichuang shares between June 21, 2023, and December 23, 2023, and sold or held after December 23, 2023, can also initiate claims [3][6].

登录新浪财经APP 搜索【信披】查看更多考评等级 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 2025年12月2日，上海久诚律师事务所股票索赔律师许峰代理的东方通（300379）虚假陈述投资者索赔 案再向北京金融法院提交一次立案。 许峰律师代理的东方通投资者索赔案已多次向北京金融法院提交立案，目前正在等待法院的下一步安 排。律师团队同步还在继续推进后续案件的立案工作，还在继续接受其他投资者的索赔委托。（许峰律 师专栏） 2025年11月25日晚，东方通公告收到证监会下发的《行政处罚决定书》，经查明，东方通存在以下违法 事实： 一、东方通2019年、2020年、2021年、2022年年度报告信息披露存在虚假记载 2018年12月，东方通收购泰策科技100%股权，泰策科技成为东方通全资子公司。2019年至2022年期 间，东方通通过泰策科技虚构业务、提前确认收入等方式虚增收入、利润，导致东方通披露的2019年至 2022年年度报告存在虚假记载。 ...

上海沪紫律师事务所刘鹏律师团队已收到不少投资者的报名需求，部分案件已递交立案。符合于2023年 10月28日-2025年4月28日期间买入，并在2025年4月29日之后卖出或仍持有而亏损的还可参与。（长园 集团维权入口） 二、投资者索赔要求 今年4月29日，长园集团发布《关于前期会计差错更正及相关定期报告更正的公告》，对公司2023年第 三季度至2024年第三季度期间的前期会计差错进行追溯更正。 一、高层之间分歧不断 11月29日，ST长园（维权）召开2025年第七次临时股东大会。公司董事会提交的多项争议议案遭到股 东大会否决，也进一步暴露出公司股东与管理层之间的分歧。 28日晚间，公司发布的临时股东大会决议公告显示，除《关于聘任会计师事务所的议案》以90.30%的 高同意率通过外，其余公司章程修订、董事等薪酬认定等议案均遭否决。 而该公司仍需面临投资者维权诉讼，源于该公司披露的一则自查公告。公司此前自曝存在关联方非经营 性资金占用。资金占用风波不仅导致公司高管频繁更迭，更使公司经营陷入困境。 经公司自查，由董事长控制的珠海市运泰利控股发展有限公司通过第三方供应商非经营性占用上市公司 资金。 资金主要通过子公 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 一、公司披露诉讼进展 ST证通（维权）公告，截至2025年11月28日，公司收到深圳市中级人民法院向公司送达受理立案的投 资者索赔案件共计754件，涉案金额约6925.34万元。 公司表示，因该案件一审尚未判决，关于判决结果存在较大的不确定性，因此暂未计提预计负债，后续 将根据案件进展情况和会计准则的要求进行相应的会计处理。 （2）于2018年4月24日-2024年5月30日期间买入，并在2024年5月31日之后卖出或仍持有而亏损。 二、财务造假被严惩 据处罚决定书，需回溯到多年前收购的一家公司，2015年证通电子收购一公司70%股权，成为子公司， 将其纳入合并报表范围。2017年10月17日至12月4日，公司子公司与另一家公司签订6份采购合同，约定 向其采购存储设备等产品，合同金额合计2，177.4万元。2017年11月1日、2018年8月23日，子公司分别 与北京一点签订销售合同，约定将相应货物销售给北京一点，合同金额合计 2，648.14万元。上述采 购、销售业务涉及的货物未真实交付，最终导致公司2017年和2019年年报存在虚假记载。 责任编辑：韦子蓉 ...

本报（chinatimes.net.cn）记者夏高琴 南京报道 在收到证监会处罚决定一周后，*ST苏吴（600200.SH）的退市终局正式落定。 12月1日晚间，*ST苏吴发布公告，因触及重大违法强制退市情形，公司收到上海证券交易所出具的 《关于江苏吴中医药发展股份有限公司股票终止上市的决定》（下称《决定》），决定终止公司股票上 市，12月9日，其股票将进入退市整理期。 "退市后我们正常挂到三板股转系统的退市板块，公司依旧是正常生产经营的。"对于上交所的《决 定》，*ST苏吴工作人员在回应《华夏时报》记者采访时表示。 针对上述违法行为，证监会作出严厉处罚：对*ST苏吴责令改正、警告并处1000万元罚款；实际控制人 钱群山被警告、罚款1500万元并实施10年证券市场禁入；其他4名相关责任人合计被罚款550万元，罚单 总额达3550万元。并且已然触及重大违法强制退市情形。 12月1日，公司收到上海证券交易所出具的《关于江苏吴中医药发展股份有限公司股票终止上市的决 定》，根据中国证监会行政处罚认定的事实，公司披露的2020年至2023年年度报告存在虚假记载。上述 情形属于重大违法强制退市情形，交易所决定终止公司股票 ...

Core Viewpoint - The recent developments in the lawsuit against Shenzhen Infitop Technology Co., Ltd. indicate that investors who suffered losses may be eligible for compensation through a voluntary registration process on the "Sina Investor Rights Protection Platform" [1][2]. Summary by Relevant Sections Legal Proceedings - The court has issued a loss assessment report from a third-party agency regarding the ongoing lawsuit against Infitop, with the investor claims still in progress [1][4]. - On December 28, 2023, Infitop received an administrative regulatory decision from the Shenzhen Securities Regulatory Bureau, revealing that the company had discrepancies in revenue recognition and fictitious receivables, leading to inaccurate financial reports for 2019-2020 [4]. - The company disclosed a business contract worth 485 million yuan in 2019 but failed to continuously report on its execution progress, indicating violations in information disclosure [4]. - In April 2024, the auditing firm issued a qualified opinion on the 2023 financial statements and an inability to express an opinion on internal controls [4]. - From April 2024 to April 2025, Infitop issued three announcements correcting prior accounting errors, adjusting financial data for 2019-2020 [4]. - On January 25, 2025, the company received a notice of investigation from the China Securities Regulatory Commission for suspected violations of information disclosure [4]. - On June 9, 2025, Infitop disclosed an additional 18.3394 million yuan in litigation related to false statements, with cases entering judicial review [4]. Compensation Eligibility - Investors who purchased shares between April 30, 2020, and April 30, 2024, and still hold them, regardless of whether they sell after April 30, 2024, may initiate claims for compensation [3][5]. - The specific compensation scope will be determined by the court [5].

Core Viewpoint - The news discusses ongoing investor compensation cases involving Haiyue Energy and Ningke Biological, highlighting legal actions taken due to financial misconduct and false reporting by these companies [1][3]. Group 1: Haiyue Energy (600387) - Haiyue Energy has been involved in a compensation case where investors have received settlements through mediation, with ongoing efforts to accept more claims [1][2]. - The company was penalized by the China Securities Regulatory Commission (CSRC) for failing to disclose non-operating fund occupation by its controlling shareholder, which was not reported in several financial statements [1][2]. - A significant accounting error was identified, where Haiyue Energy incorrectly used the total amount method to recognize revenue, leading to an inflated revenue and cost figure of 302,081.64 million yuan, which represented 49.33% and 50.51% of the reported figures respectively [2][8]. Group 2: Ningke Biological (600165) - Ningke Biological's investor compensation case has also progressed, with a court ruling in favor of investors, and the legal team is accepting more claims [3][9]. - The company was found to have falsely reported its 2022 annual revenue, inflating it by 7,659.41 million yuan, which accounted for 11.25% of the total revenue, and profit by 7,722.20 million yuan, representing 46.59% of the total profit [9][10]. - The company failed to timely disclose significant events, including major debts, frozen bank accounts, and the suspension of key subsidiary operations [10].

Core Viewpoint - The article discusses the ongoing legal proceedings related to Infitop (002528) due to allegations of false statements, highlighting the potential for investor claims and the current status of lawsuits [1][2][3]. Group 1: Legal Proceedings - Infitop has received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation for suspected violations of information disclosure laws, leading to a formal case being opened against the company [3]. - A precedent has been set with a previous investor winning a lawsuit related to Infitop's false statements, indicating that affected investors can still file claims within the statute of limitations [1][2]. Group 2: Investor Claims - Investors who purchased Infitop shares between April 30, 2020, and April 30, 2024, and either sold or continued to hold their shares after April 30, 2024, are eligible to initiate claims for compensation [2][3]. - The law firm representing the investors has received a report on the calculation of investor losses, and they are actively pursuing further claims and accepting new clients for compensation [1][2].